Meta AnalysisID 5647
鳖甲煎丸联合恩替卡韦对肝硬化代偿期血清肝纤维化标志物影响的Meta分析
CRD42019135402
To evaluate effects of Biejiajian Pill combined with Entecavir and Entecavir alone on four serum liver fibrosis markers of compensatory period of cirrhosis.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5647
- Evidence Id
- 14205
- Core Evidence Id
- 14205
- Source Meta Analysis Id
- 5730
- Herb2 Meta Analysis Id
- HBMA005730
- Crd Id
- CRD42019135402
- Title
- Meta-analysis of influences of Biejia Pill combined with Entecavir on serum liver fibrosis markers of compensatory period of cirrhosis
- Review Question
- To evaluate effects of Biejiajian Pill combined with Entecavir and Entecavir alone on four serum liver fibrosis markers of compensatory period of cirrhosis.
- Study Type Included
- Randomized controlled trials
- Condition Being Studied
- Cirrhosis is a kind of common chronic liver disease pathology results, the main pathological feature is the formation of liver fibrosis, which is characterized by fibroblast, accumulation of abnormal muscle fibroblasts, the formation of fibrous scar tissue and extracellular matrix (ECM) protein synthesis and deposition, also accompanied by the micro circulation barrier. In the early stages of cirrhosis, liver fibrosis as the formation of recurrent liver damage phenomenon of healing reaction is reversible. In recent years, Chinese medicine has made great progress in the treatment of liver fibers. The treatment objective is prolong the HBV replication time, decrease the degree of inflammatory necrosis and fibrosis of liver cells. It is also important to reduce the occurrence of liver decompensation and improve and prolong the survival time of patients.
- Participant
- Inclusion criterion: (1) Subjects: liver cirrhosis compensation period, and the four indicators of serum liver fibrosis, namely hyaluronic acid (HA), laminin (LN), pre-type-iii collagen (PC III), and type IV collagen (Iv-c), showed at least three abnormalities, without the age and sex limitation. (2) Study design type: randomized controlled trial (RCT). (3) Intervention: in the treatment group, entecavir was combined with Biejiajian pill, but not with other drugs. In the control group, entecavir was only used. (4) Neither the treatment group nor the control group received additional antiviral and antihepatic fibrosis treatment. (5) Outcome measures: at least three of the four indicators of serum liver fibrosis (including three). Exclusion criterion (1) Decompensation of liver cirrhosis, chronic hepatitis with liver cancer, liver failure and other serious cardiovascular, cerebrovascular, endocrine, urinary and hematological diseases; (2) Literature review; (3) Literature that is vague or cannot be obtained in full; (4) Repeatedly published and repeatedly included literature
- Animal
- Human Disease Modelled
- Intervention
- Biejiajian pill combined with Entecavir on four markers of serum hepatic fibrosis during the compensatory stage of liver cirrhosis. In order to make an objective evaluation for the combined treatment of cirrhosis.
- Comparator Control
- Entecavir was only used.
- Main Outcome
- Liver function test results; the four indicators of serum liver fibrosis, namely hyaluronic acid (HA), laminin (LN), pre-type-iii collagen (PC III), and type IV collagen (Iv-c), Measures of effect We will measure the outcome in the beginning and at the end of the treatment course
- Outcome Measure
- Additional Outcome
- 1. Quality of life 2. Adverse events Measures of effect We will measure the outcome at the end of the treatment course
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Biomarkers; Fibrosis; Humans; Liver Cirrhosis
- Contact
- Tianyao Zhang [email protected]
- Organisational Affiliation
- Chengdu University of Traditional Chinese Medicine http://www.cdutcm.edu.cn/
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-05-14
- Registration Date
- 2019-10-07
- Anticipated Start Date
- 2019-05-04
- Anticipated Completion Date
- 2019-09-01
- Title Cn
- 鳖甲煎丸联合恩替卡韦对肝硬化代偿期血清肝纤维化标志物影响的Meta分析
- Title En
- Meta-analysis of influences of Biejia Pill combined with Entecavir on serum liver fibrosis markers of compensatory period of cirrhosis
- Bilingual Status
- complete